|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cirrhotic patients and older people显示文摘The global population is aging,and so the number of older cirrhotic patients is increasing.Older patients are characterised by a risk of frailty and comorbidities,and age is a risk factor for mortality in cirrhotic patients.The incidence of nonalcoholic fatty liver disease as an aetiology of cirrhosis is increasing,while that of chronic viral hepatitis is decreasing.Also,cirrhosis is frequently idiopathic.The management of portal hypertension in older cirrhotic patients is similar to that in younger patients,despite the greater risk of treatment-related adverse events of the former.The prevalence of hepatocellular carcinoma increases with age,but its treatment is unaffected.Liver transplantation is generally recommended for patients<70 years of age.Despite the increasing prevalence of cirrhosis in older people,little data are available and few recommendations have been proposed.This review suggests that comorbidities have a considerable impact on older cirrhotic patients. | Paul Carrier Marilyne Debette-Gratien Jérémie Jacques Véronique Loustaud-Ratti | 2019 | World Journal of Hepatology2019，11，9： | 6 |
| 2 | Ribavirin:Past,present and future显示文摘Before the advent of direct acting antiviral agents(DAAs) ribavirin, associated to pegylated-interferon played a crucial role in the treatment of chronic hepatitis C, preventing relapses and breakthroughs. In the present era of new potent DAAs, a place is still devoted to the drug. Ribavirin associated with sofosbuvir alone is efficient in the treatment of most cases of G2 infected patients. All options currently available for the last difficult-to-treat cirrhotic G3 patients contain ribavirin. Reducing treatment duration to 12 wk in G1 or G4 cirrhotic compensated patients is feasible thanks to ribavirin. Retreating patients with acquired anti NS5 A resistance-associated variants using ribavirin-based strategies could be useful. The addition of ribavirin with DAAs combinations however, leads to more frequent but mild adverse events especially in cirrhotic patients. Preliminary data with interferon-free second generation DAAs combinations without ribavirin suggest that future of the drug is jeopardized even in difficult-totreat patients: The optimization of ribavirin dosage according to an early monitoring of blood levels has been suggested to be relevant in double therapy with peginterferon or sofosbuvir but not with very potent combinations of more than two DAAs. | Véronique Loustaud-Ratti Marilyne Debette-Gratien Jérémie Jacques Sophie Alain Pierre Marquet DenisSautereau Annick Rousseau Paul Carrier | 2016 | World Journal of Hepatology2016，8，2： | 3 |
| 3 | HCV ‐associated B ‐cell non‐ H odgkin lymphomas and new direct antiviral agents显示文摘 | Paul Carrier Arnaud Jaccard Jérémie Jacques Tessa Tabouret Marilyne Debette‐Gratien Julie Abraham Laura Mesturoux Pierre Marquet Sophie Alain Denis Sautereau Marie Essig Véronique Loustaud‐Ratti | 2015 | Liver Int2015，，10： | 2 |
| 4 | European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift显示文摘The latest Association Fran?aise pour l'Etude du Foie-French Association for Study of the Liver(AFEF) and European Association for the Study of the Liver(EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus(HCV). The AFEF recommendations focus on the elimination of HCV infection on a national level by preventing reinfection, in less than ten years. This goal involves the facilitation of patients' management in a simplified pathway by increasing screening procedures and access to pangenotypic treatments mainly in the 'reservoir' population of people who inject drugs and migrants. Even in the complex pathway of patients with previous comorbidities, AFEF takes the option of a therapeutic simplification. The EASL guidelines position themselves on the state of the art with a precise description of all therapeutic options available, without separating simplified and complex pathways even if they take into account the epidemiological evolution of difficult-to-treat populations. | Véronique Loustaud-Ratti Marilyne Debette-Gratien Paul Carrier | 2018 | World Journal of Hepatology2018，10，10： | 2 |
| 5 | Critical assessment of the nuclear import of plasmid during cationic lipid - mediated gene transfer显示文摘 | ESCRIOU V CARRIERE M BUSSONE F | 2001 | J Gene Med2001，3，2： | 1 |
| 6 | Activity of hepatocyte nuclear factor 1α and hepatocyte nuclear factor 1β isoforms is differently affected by the inhibition of protein phosphatases 1/2A显示文摘 | Carriere V Lacasa M Rousset M | | 0，，： | 1 |
| 7 | IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo 显示文摘 | Carriere V Roussel L Ortega N | 2007 | Proc Nat Acad Sci U S A2007，104，1： | 1 |
| 8 | Coalescence in draining foams 显示文摘 | CARRIER V COLIN A | 2003 | Langmuir2003，19，1： | 1 |
| 9 | IL-33,the IL-1-like cytokine ligand for ST2 receptor,is a chromatin-associated nuclear factor in vivo显示文摘 | Carriere V Roussel L Ortega N | 2007 | Proc Natl Acad Sci U S A2007，104，1： | 1 |
| 10 | A novel, sensitive, and specific RT-PCR iechnique for quantitation of hepatitis C virus replication 显示文摘 | Carriere M Pene V Breiman A | 2007 | J Med Virol2007，79，2： | 1 |
| 11 | Critical assess-ment of the nuclear import of plasmid during cationic lipid-media- ted gene transfer显示文摘 | ESCRIOU V CARRIERE M BUSSONE F | 2001 | J Gene Med2001，3，2： | 1 |
| 12 | IL-33, the IL-l-like cyto- kine ligand for ST2 receptor, is a chromatin-assoeiated nuclear fac- tor in vivo 显示文摘 | Carriere V Roussel L Ortega N | 2007 | Proe Natl Acad Sci U S A2007，104，1： | 1 |
| 13 | Cochlear implant failure: Is an auditory brainstem implant the answer? 显示文摘 | Colletti V Carrier M Miorelli V | 2004 | Acta Otolaryngol2004，124，4： | 1 |
| 14 | IL-33, the IL-l-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo 显示文摘 | Carriere V Roussel L Ortega N | 2007 | Proc Natl Acad Sci USA2007，104，1： | 1 |
| 15 | IL-33, the IL-1 like cytokine ligand for ST2 receptor, is a chromatin- associated nuclearfactor in vivo 显示文摘 | Carriere V Roussel L Ortega N | 2007 | Proc Natl Acad Sci U S A2007，104，1： | 1 |
| 16 | Distribution of ginkgolides and terpenoid biosynthetic activity in Ginkgo biloba显示文摘 | Carrier D J Van Beek T A Heijden R V D | 1998 | Phytochemistry1998，48，1： | 1 |
| 17 | Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node显示文摘 | Carriere V Coliddon R Jiguet-Jiglaire C | 2005 | Cancer Res2005，65，11： | 1 |
| 18 | IL-33, the IL-l-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo显示文摘 | Carriere V Roussel L Ortega N | 2007 | Proe Natl Acad Sci U S A2007，104，1： | 1 |
| 19 | IL-33,the IL-1-like cytokine ligand for ST2 receptor,is a chromatin-associated nuclear factor in vivo显示文摘 | Carriere V Roussel L Ortega N | 2007 | Proc Natl Acad Sci USA2007，104，1： | 1 |
| 20 | Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node 显示文摘 | Carriere V Coliddon R Jiguet-Jiglaire C | 2005 | Cancer Res2005，65，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员